Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 12/20 | 0.43 |
| ▸ | HSD11B2 | P80365 | 7/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5911442 | 0.79 | HSD11B1 (0.49) | HSD11B1HSD11B2P2RX7 | |
| SCHEMBL25464169 | 0.76 | LMNA (0.50) | AVPR1AHSD11B1P2RX7FFAR2ALDH1A1 | |
| SCHEMBL3143316 | 0.72 | EPHX1 (0.55) | AVPR1AHSD11B1P2RX7ALDH1A1MAPT | |
| SCHEMBL4966484 | 0.72 | HDAC4 (0.46) | AVPR1AHSD11B1ALDH1A1 | |
| SCHEMBL3154279 | 0.71 | PTGDR (0.36) | HSD11B1HSD11B2ALDH1A1PTGDR | |
| SCHEMBL3149733 | 0.71 | POLB (0.39) | HSD11B1HSD11B2ALDH1A1MAPT | |
| SCHEMBL3173597 | 0.71 | HSD11B1 (0.71) | HSD11B1HSD11B2 | |
| SCHEMBL2021090 | 0.70 | HSD11B1 (0.72) | HSD11B1HSD11B2 | |
| SCHEMBL13348709 | 0.70 | P2RX7 (0.39) | AVPR1AHSD11B1P2RX7FFAR2ACKR3 | |
| SCHEMBL13313613 | 0.69 | P2RX7 (0.45) | AVPR1AP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | claimed |
| EP-1768954-A4 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-05-28 | — | — | EP | claimed |
| EP-1768954-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-04 | — | — | EP | claimed |
| WO-2006002361-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | claimed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687665-B2 | 2-(4-Chlorophenyl)-N-[(1R,2R)-2-(benzyloxy)cyclohexyl]-2-methylpropanamide; modulators of 11- beta hydroxyl steroid dehydrogenase type 1 and/or mineralocorticoid receptor | INCYTE CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1768954-A4 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1768954-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006002361-A2 | 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | INCYTE CORPORATION | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137401-A1 | 2-METHYLPROP ANAMIDES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 414/4885HSD11B1 1/4885HSD11B2 2/4885 |
| US-20050288329-A1 | 2-Methylprop anamides and their use as pharmaceuticals | HSD11B1, HSD11B2, HSD3B1 | AVPR1A 414/4885HSD11B1 1/4885HSD11B2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.